Efficacy and safety of clopidogrel and aspirin in patients with chronic coronary syndrome: a systematic review and meta-analysis.
Аннотация
OBJECTIVE
To systematically evaluate and compare the efficacy and safety of clopidogrel and aspirin, as well as their combination, in patients with chronic coronary syndrome (CCS), and to provide evidence-based support for long-term antiplatelet therapy in stable coronary artery disease.
METHODS
A comprehensive literature search was conducted in CNKI, WanFang, PubMed, Web of Science, and Embase databases from January 1990 to July 2025. Randomized controlled trials comparing clopidogrel and aspirin as monotherapy or in combination in patients with CCS were included. Relative risk (RR) or mean difference (MD) with 95% confidence intervals (CI) were pooled using fixed- or random-effects models according to heterogeneity. Publication bias and sensitivity analyses were performed where appropriate.
RESULTS
A total of 24 studies involving patients with chronic coronary syndrome were included. Compared with aspirin monotherapy, clopidogrel monotherapy was associated with a numerically lower incidence of myocardial infarction, although the difference was not statistically significant. No significant difference in the risk of serious bleeding events was observed between clopidogrel and aspirin. Combination therapy with clopidogrel and aspirin was associated with a higher treatment response rate and a tendency toward reduced angina frequency compared with aspirin alone; however, substantial heterogeneity was present, and the observed benefits were mainly confined to subjective or semi-quantitative outcomes. The incidence of common adverse reactions, including gastrointestinal discomfort, dizziness, and headache, was numerically lower in the combination therapy group, but these differences did not reach statistical significance.
CONCLUSION
In patients with chronic coronary syndrome, clopidogrel represents a reasonable alternative to aspirin for long-term antiplatelet therapy, with comparable efficacy and safety. Combination therapy with clopidogrel and aspirin may offer modest improvements in symptom-related outcomes; however, these findings should be interpreted cautiously due to heterogeneity, potential publication bias, and the subjective nature of some endpoints. Individualized antiplatelet strategies based on ischemic and bleeding risk remain essential in stable coronary artery disease.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251108327.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.